Johnson & Johnson Medical Technology recently announced,Will expand its R&D and Innovation (RD&I) business layout in Ireland. This expansion will focus on the company's base in Galway, which serves as both an R&D innovation hub and the core execution site for the Neuro Thromboembolism Initiative (NTI)., its NTI program focuses on unmet medical needs in neurovascular diseases, driving technological innovation in the field of stroke treatment.

This move is not only an important step in its global strategic layout but also reflects the vigorous development and intense market competition in the neurovascular sector.

The Galway site in Ireland is the core hub for Johnson & Johnson's neurovascular R&D, having undergone multiple rounds of expansion since its establishment in 2017.As a core unit of Johnson & Johnson Medical Technologies dedicated to neurovascular technology R&D, Cerenovus has long been committed to the innovation of stroke treatment devices and other products. The research and development upgrade of the Galway Center of Excellence will further deepen its exploration in the field of stroke treatment solutions.

Previously, Johnson & Johnson Medical TechnologyThe cutting-edge innovation center launched here in 2022 has officially opened this year, and the Galway site is becoming an innovation hub connecting Europe and even the globe.

Michael Gilvarry, R&D Leader of Johnson & Johnson Medical Technologies' Neurovascular Division and General Manager of the Galway site, stated: "By expanding the scope of R&D from ischemic stroke to chronic subdural hematoma and other neurovascular diseases, the Galway team is applying innovative thinking, specialized knowledge, and engineering expertise to find solutions for these life-threatening conditions. Ireland is a key node in our global innovation network, and this investment demonstrates our long-term commitment to advancing the neurovascular field in the region, ultimately benefiting patients worldwide."

Michael Lohan, CEO of IDA Ireland, pointed out: "Galway and the western region of Ireland have long been a core hub for Europe's medical technology industry, and our ongoing collaboration with Johnson & Johnson Medical in the neurovascular field is a clear example of this region as a significant innovation highland. The R&D work at the Galway site aligns closely with our new 'Smart Adaptation' strategy, which will not only create high-skilled job opportunities for local talent but also reshape the future landscape of global stroke treatment through cutting-edge innovations born in western Ireland."

Johnson & Johnson, with its two core brands Cerenovus and Codman Neuro, ranks among the top in the global neurointerventional device market.In 2024, Johnson & Johnson's cardiovascular business revenue reached $7.707 billion, a significant year-over-year increase of 21.4%. The innovation and market penetration of neurovascular-related products were among the core growth drivers.

The third quarter of 2025,Johnson & Johnson Medical Technologies' revenue increased by 6.8% year-over-year to $8.4 billion, with cardiovascular business maintaining a high growth rate of over 22%., demonstrating the market competitiveness of core tracks including neurovascular.

At the 8th CIIE, Johnson & Johnson Medical Technologies showcased products including the "Asian debut" CEREGLIDE 71 Distal Access Catheter, presenting a full-process stroke surgery solution from access creation to thrombectomy, highlighting the competitiveness of its product portfolio.

CEREGLIDE 71Can be used for access establishment in the neurovascular system, reaching up to the M1-M2 segments of the brain, assisting in rapid access establishment, and buying more treatment time for stroke patients.

In March 2025, Michael Bodner announced his appointment as Chairman of the Electrophysiology and Neurovascular Group, further optimizing the business leadership structure.Began focusing on the company's cardiac recovery and circulation recovery departments in 2023.Previously, he served as the Global President of Biosense Webster, overseeing Johnson & Johnson's electrophysiology business, and also held the position of Vice President of U.S. Sales, Marketing, and Global Technical Services at Biosense Webster. During his leadership of the electrophysiology division, he was also responsible for supervising the integration following the acquisition of Abiomed in 2022.

The addition of new leadership has, to a certain extent, quelled previous rumors about the sale of this department.

As a major global health challenge, neurovascular diseases are entering a golden period of synchronized technological breakthroughs and market scale growth, becoming a high-potential track in the medical technology industry.

Globally, the demand for neurovascular-related devices continues to rise. In China alone, the market size for neurointerventional devices has surpassed 5 billion yuan in 2024 and is still maintaining a growth trend.

In China, the number of stroke patients ranks first globally. Driven by policies, the substitution of domestically produced devices is accelerating. By 2024, the market size of neurointerventional devices has exceeded 5 billion yuan and is expected to grow further in the future.In the first half of 2025, against the backdrop of a 50% reduction in the total amount of mergers and acquisitions in China's pharmaceutical industry, the neurointervention sector completed four M&A transactions, becoming one of the subfields with the highest number of deals.Chinese neurointerventional companies such as Peijia Medical, Xinwei Medical, and GuiChuang Tongqiao are continuously enhancing their industry competitiveness by leveraging cost advantages and innovative products (such as thrombectomy stents and microcatheters). Additionally,Through centralized procurement, the market share of Chinese-produced neurointerventional products surged from less than 10% to 26%. Going forward,器械之家 will continue to monitor how this high-growth track will compete.